A new boost for innovation in nanomedicine and non‑animal drug development!

The European Medicines Agency (EMA) and the U.S. FDA have jointly released 10 Guiding Principles for Good AI Practice in Drug Development, establishing a shared transatlantic foundation for the responsible use of AI across the entire medicines lifecycle.

This development strongly resonates with the mission of NAP4DIVE, where AI‑powered tools, in‑silico simulations, and non‑animal models are central to designing safer, smarter nanoparticles for crossing the blood–brain barrier.

Here are the guide principles…